Pharmacists Richard Emery, left, and Karen Nolan, wheel a box containing the Pfizer-BioNTech COVID-19 vaccine next to a storage freezer as it arrives at Rhode Island Hospital in Providence, R.I, Monday, Dec. 14, 2020. (AP Photo/David Goldman)
By Lauran Neergaard
Hospital workers begin unloading precious frozen vials of COVID-19 vaccine Monday, with the first vaccinations against a scourge that has killed nearly 300,000 Americans expected later in the day.
“It feels like the cavalry is arriving,” Robert C. Garrett, CEO of Hackensack Meridian Health, said as New Jersey’s largest health network awaited delivery.
Shots made by Pfizer Inc. and its German partner BioNTech are the first authorized for emergency use by the Food and Drug Administration -- beginning what will become the largest vaccination campaign in U.S. history. Several other countries also have OK'd the vaccine, including the U.K., which started vaccinating last week.
For health care workers who, along with nursing home residents, will be first in line for vaccination, hope is tempered by grief and the sheer exhaustion of months spent battling a coronavirus that still is surging in the U.S. and around the world.
“This is mile 24 of a marathon. People are fatigued. But we also recognize that this end is in sight,” said Dr. Chris Dale of Swedish Health Services in Seattle.
Packed in dry ice to stay at ultra-frozen temperatures, the first of nearly 3 million doses being shipped in staggered batches this week made their way by truck and by plane around the country Sunday from Pfizer’s Kalamazoo, Michigan, factory. Once they arrive at distribution centers, each state directs where the doses go next.
Some hospitals across the country spent the weekend tracking their packages, refreshing FedEx and UPS websites for clues.
More of the Pfizer-BioNTech vaccine will arrive each week. And later this week, the FDA will decide whether to green light the world’s second rigorously studied COVID-19 vaccine, made by Moderna Inc.
Now the hurdle is to rapidly get vaccine into the arms of millions, not just doctors and nurses but other at-risk health workers such as janitors and food handlers — and then deliver a second dose three weeks later.
“We’re also in the middle of a surge, and it’s the holidays, and our health care workers have been working at an extraordinary pace,” said Sue Mashni, chief pharmacy officer at Mount Sinai Health System in New York City.
Plus, the shots can cause temporary fever, fatigue and aches as they rev up people's immune systems, forcing hospitals to stagger employee vaccinations.
A wary public will be watching closely to see whether health workers embrace vaccination. Just half of Americans say they want to get vaccinated, while about a quarter don’t and the rest are unsure, according to a recent poll by The Associated Press-NORC Center for Public Health Research.
The FDA, considered the world’s most strict medical regulator, said the Pfizer-BioNTech vaccine appears safe and strongly protective -- and laid out the data behind it in a daylong public meeting last week for scientists and consumers alike to see.
“Please people, when you look back in a year and you say to yourself, ‘Did I do the right thing?’ I hope you’ll be able to say, ‘Yes, because I looked at the evidence,’” Dr. Francis Collins, director of the National Institutes of Health, said Sunday on NBC’s Meet the Press. “People are dying right now. How could you possibly say, ‘Let’s wait and see.’”
Still, emergency use means the vaccine was cleared for widespread use before a final study in nearly 44,000 people is complete -- and that research is continuing to try to answer additional questions. While effective against COVID-19 illness, it’s not yet clear if vaccination will stop the symptomless spread that accounts for half of all cases.
The shots still must be studied in children, and during pregnancy. But the American College of Obstetricians and Gynecologists said late Sunday that vaccination should not be withheld from pregnant women who otherwise would qualify.
While the vaccine was determined to be safe, regulators in the U.K. are investigating several severe allergic reactions. The FDA’s instructions tell providers not to give it to those with a known history of severe allergic reactions to any of its ingredients.
AP journalists Tamara Lush and Kathy Young contributed to this report.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
On this episode of Cheddar Innovates: Founder of Unlimited Tomorrow breaks down how he is creating completely 3D printed prosthetics to make them more affordable, customizable, and accessible; Chief Technology Officer of Zebra Technologies explains what the future of collaboration between robots and humans may look like; A look at Curiosity Stream's 'Mystery of the Roman Skulls.'
Each year about 5,000 people are diagnosed with ALS. This is such an important conversation. A disease that can weaken a patient's muscles and impact physical function. However, one research company says that could all change soon. Coya Therapeutics has developed a way to isolate a patient problematic T-cells in order to help ultimately slow the decline of not just ALS, but potentially Alzheimer's and other neurodegenerative diseases as well. Founder and Chief Executive Officer at Coya Therapeutics, Dr. Howard Berman, joined Cheddar to discuss more.
In the fight against climate change, much of the conversation revolves around reducing greenhouse gases like carbon dioxide or methane - and attempting to raise oxygen levels. But there's another gas - hydrogen - that could play a big role in the fight for the climate. Marco Alvera, CEO of Italian energy infrastructure company Snam and author of the book, 'The Hydrogen Revolution,' joined Cheddar Climate to explain the role hydrogen plays in helping achieve a net-zero future.
Americans looking to purchase at-home COVID-19 tests will now have to shell out a bit more money after an agreement expired between the White House and companies to sell the tests at cost. The price of Abbot's BinaxNow test kit from October to December was $14 apiece; on Tuesday, Walmart's website listed the test for $19.88, and Kroger listed the tests for $23.99. Carbon Health Regional Clinical Director Dr. Bayo Curry-Winchell joined Cheddar News' Closing Bell to discuss the impact higher prices will have as the nation experiences another surge in cases.
As millions of kids go back to school, districts across the country are determined to keep class in person, despite a surge in COVID cases. In New York City, Mayor Eric Adams has vowed to keep the nation's largest school system open amid Omicron, citing the disastrous effect of remote learning on students. Oswald Feliz, NYC council member who sits on the health and education committee, joined Cheddar to discuss the city's plan to combat the recent surge and keep kids in school.
Schools across the country are determined to keep class in session, despite the rapidly-spreading Omicron variant. While many parents prefer in-person learning, they also worry whether the current public health guidelines will be enough to protect their kids. Erin Richards, national education reporter for USA Today, joined Cheddar to discuss how are schools are preparing for the surge to avoid another round of remote learning.
With the annual CES convention underway amid COVID, HP unveiled rolled out a number of new products virtually this year, including new gaming PCs and 4K display monitors. But as industries look toward a greener future, HP is working with the climate crisis in mind. James McCall, chief sustainability officer at HP, joined Cheddar's Kristen Scholer to discuss the company's climate goals, which includes reducing its carbon footprint to net-zero by 2040. He admitted that reaching the ambitious goal will be difficult because much of the company's emissions totals come from third parties. "A large part of our footprint is outside of HP's direct control. A lot of it comes either from our incoming supply chain, the materials, our manufacturing process, or about 30 to 40 percent of it comes from our consumer-use base," McCall told Cheddar.
Pfizer and BioNTech are working to develop an mRNA-based shingles vaccine following the success of the COVID-19 shot. This latest collaboration will mark the third time the pharmaceutical companies have worked together on a vaccine.
The potential collapse of the Thwaites glacier in Antarctica has been deemed a potential "doomsday event" — researchers and scientists say its melting and collapse could raise global sea levels by at least two feet, enough to destroy coastal communities around the world. One team of scientists is traveling to the Thwaites glacier to drill below in order to gauge current ocean temperatures and attempt to model possible outcomes. David Holland, professor at NYU and Principal Investigator for the International Thwaites Glacier Collaboration, joins Cheddar Climate to discuss the glacier's potential collapse, his team's research plan, and more.
As winter break wraps up and COVID-19 cases hit record levels, the majority of school districts are returning to in-person classes. While some public schools in large cities have shifted to remote learning for the beginning of the year, the schools that are reopening campuses are determined to avoid the academic, social, and logistical challenges that come with a virtual classroom. Cheddar News is joined by Keith Powers, NYC Council Member, to discuss.
